Skip to content

Phase 3 trial suggests benefit of MDMA‐assisted therapy for PTSD

The Brown University Psychopharmacology Update August 1, 2021 DOI: 10.1002/pu.30752 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Intervention MDMA
Topics MDMA PTSD
Key findings Adding MDMA to manualized therapy for PTSD resulted in significant symptom improvement and reduced functional impairment relative to placebo, with no increase in adverse events.

Abstract

Adding 3,4‐methylenedioxymethamphetamine (MDMA) to manualized therapy for post‐traumatic stress disorder (PTSD) resulted in significant symptom improvement and reduced functional impairment relative to placebo in a Phase 3 trial. The researchers observed no increase in adverse events from use of MDMA, including no increase in suicidality. Study results were published online May 10 in Nature Medicine.

Related reading